Therapeutic Potential of Self-Administered Subcutaneous Rozanolixizumab in Myasthenia Gravis: Rachana K. Gandhi Mehta, MBBS
The assistant professor of neurology at Wake Forest School of Medicine provided clinical insight on MG0020, a phase 3 trial assessing a self-administration of rozanolixizumab through a syringe driver. [WATCH TIME: 3 minu]
WATCH TIME: 2 minutes
"If patients would have more self-administration options for rozanolixizumab, they can do infusions on their own, without relying on nurses or going to the infusion center. It’s really, really innovative, and I think it’s really cool."
Rozanolixizumab is a humanized high-affinity, anti-human neonatal Fc receptor (FcRn) monoclonal antibody targeting the immunoglobulin G. In mid-2023, the FDA approved the agent as a treatment for adults with generalized myasthenia gravis (gMG) who are either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, the most common subtypes of gMG. With the approval, it became the first marketed treatment to treat both subtypes of the disease.
MG0020, a phase 3, open-label, randomized, crossover study, is a new innovative trial that tests whether patients can safely self-administer rozanolixizumab using a syringe driver and manual push method. To date, 75 patients with gMG have been screened and 55 were randomized. In the study, patients receive once-weekly rozanolixizumab for 18 consecutive weeks consisting of a 6-week self-administration training period followed by two 6-week self-administration periods. After training, patients are randomly assigned 1:1 to the syringe driver or manual push self-administration method, subsequently crossing over to the alternative method.
The design of the trial was presented at the
REFERENCES
1. Mehta RG, Bril V, Antozzi C, et al. Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: clinical study design. Presented at: 2024 AANEM Annual Meeting; October 15-18; Savannah, GA. ABSTRACT 164
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025